Dose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers von Sakamuri, D., Kato, S., Huang, H.J., Naing, A., Holley, V.R., Patel, S., Piha-Paul, S.A., Tsimberidou, A.M., Hong, D.S., Meric-Bernstam, F., Janku, F.

Volltext